Literature DB >> 25455734

Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States.

Katherine C Fuh1, Jacob Y Shin1, Daniel S Kapp2, Rebecca A Brooks1, Stefanie Ueda1, Renata R Urban3, Lee-May Chen1, John K Chan4.   

Abstract

OBJECTIVE: To compare the racial differences in treatment and survival of Asian-Americans and White patients with epithelial ovarian cancer.
METHODS: Data were obtained from the Surveillance, Epidemiology, and End Results Program between 1988 and 2009 and analyzed using Chi-squared tests, Kaplan-Meier methods, and Cox regression analysis.
RESULTS: Of the 52,260 women, 3932 (7.5%) were coded as Asian, and 48,328 (92.5%) were White. The median age of Asians at diagnosis was 56 vs. 64 years for the Whites (p<0.001). Asians were more likely to undergo primary surgery, have an earlier stage of disease, have a diagnosis of a non-serous histology, and have lower grade tumors. The 5-year disease-specific survival (DSS) of Asians was higher compared to Whites (59.1% vs. 47.3%, p<0.001). On a subset analysis, Vietnamese, Filipino, Chinese, Korean, Japanese, and Asian Indian/Pakistani ethnicities had 5-year DSS of 62.1%, 61.5%, 61.0%, 59.0%, 54.6%, and 48.2%, respectively (p=0.015). On multivariate analysis, age at diagnosis, year of diagnosis, race, surgery, stage, and tumor grade were all independent prognostic factors for survival. Asians were further stratified to U.S. born versus those who were born in Asia and immigrated. Asian immigrants presented at a younger age compared to U.S. born Asians. Immigrants were found to have an improved 5-year DSS when compared to U.S. born Asians and Whites of 55%, 52%, and 48%, respectively (p<0.001).
CONCLUSION: Asians were more likely to be younger, undergo primary surgery, have an earlier stage of disease, non-serous histology, lower grade tumors, and higher survival.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Immigrants; Ovarian cancer; Racial differences; Survival outcomes

Mesh:

Year:  2014        PMID: 25455734     DOI: 10.1016/j.ygyno.2014.10.009

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  22 in total

1.  Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.

Authors:  Katherine C Fuh; James J Java; John K Chan; Daniel S Kapp; Bradley J Monk; Robert A Burger; Robert C Young; David S Alberts; William P McGuire; Maurie Markman; Jeffrey Bell; Robert F Ozols; Deborah K Armstrong; Carol Aghajanian; Michael A Bookman; Robert S Mannel
Journal:  Gynecol Oncol       Date:  2019-06-19       Impact factor: 5.482

2.  Prognostic factors in Asian and white American patients with cervical cancer, considering competing risks.

Authors:  Y Hou; S Guo; J Lyu; Z Lu; Z Yang; D Liu; Z Chen
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

3.  Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival.

Authors:  Elisa V Bandera; Valerie S Lee; Lorna Rodriguez-Rodriguez; C Bethan Powell; Lawrence H Kushi
Journal:  Clin Cancer Res       Date:  2016-08-12       Impact factor: 12.531

4.  Impact of age on clinicopathological features and survival of epithelial ovarian neoplasms in reproductive age.

Authors:  Maya Hanatani; Nobuhisa Yoshikawa; Kosuke Yoshida; Satoshi Tamauchi; Yoshiki Ikeda; Kimihiro Nishino; Kaoru Niimi; Shiro Suzuki; Michiyasu Kawai; Hiroaki Kajiyama; Fumitaka Kikkawa
Journal:  Int J Clin Oncol       Date:  2019-09-20       Impact factor: 3.402

5.  Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

Authors:  John K Chan; Mark F Brady; Richard T Penson; Helen Huang; Michael J Birrer; Joan L Walker; Paul A DiSilvestro; Stephen C Rubin; Lainie P Martin; Susan A Davidson; Warner K Huh; David M O'Malley; Matthew P Boente; Helen Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2016-02-25       Impact factor: 91.245

6.  Predictors of survival trajectories among women with epithelial ovarian cancer.

Authors:  Lauren C Peres; Sweta Sinha; Mary K Townsend; Brooke L Fridley; Beth Y Karlan; Susan K Lutgendorf; Eileen Shinn; Anil K Sood; Shelley S Tworoger
Journal:  Gynecol Oncol       Date:  2019-12-12       Impact factor: 5.482

7.  Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.

Authors:  Lauren C Peres; Kara L Cushing-Haugen; Martin Köbel; Holly R Harris; Andrew Berchuck; Mary Anne Rossing; Joellen M Schildkraut; Jennifer A Doherty
Journal:  J Natl Cancer Inst       Date:  2019-01-01       Impact factor: 13.506

8.  Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.

Authors:  Kate Lawrenson; Fengju Song; Dennis J Hazelett; Siddhartha P Kar; Jonathan Tyrer; Catherine M Phelan; Rosario I Corona; Norma I Rodríguez-Malavé; Ji-Hei Seo; Emily Adler; Simon G Coetzee; Felipe Segato; Marcos A S Fonseca; Christopher I Amos; Michael E Carney; Georgia Chenevix-Trench; Jiyeob Choi; Jennifer A Doherty; Weihua Jia; Gang J Jin; Byoung-Gie Kim; Nhu D Le; Juyeon Lee; Lian Li; Boon K Lim; Noor A Adenan; Mika Mizuno; Boyoung Park; Celeste L Pearce; Kang Shan; Yongyong Shi; Xiao-Ou Shu; Weiva Sieh; Pamela J Thompson; Lynne R Wilkens; Qingyi Wei; Yin L Woo; Li Yan; Beth Y Karlan; Matthew L Freedman; Houtan Noushmehr; Ellen L Goode; Andrew Berchuck; Thomas A Sellers; Soo-Hwang Teo; Wei Zheng; Keitaro Matsuo; Sue Park; Kexin Chen; Paul D P Pharoah; Simon A Gayther; Marc T Goodman
Journal:  Gynecol Oncol       Date:  2019-03-19       Impact factor: 5.482

9.  Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes.

Authors:  Jennifer Anne Doherty; Lauren Cole Peres; Chen Wang; Gregory P Way; Casey S Greene; Joellen M Schildkraut
Journal:  Curr Epidemiol Rep       Date:  2017-07-10

10.  Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response.

Authors:  A N van den Pol; X Zhang; E Lima; M Pitruzzello; N Albayrak; A Alvero; J N Davis; G Mor
Journal:  Virology       Date:  2020-11-12       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.